Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 69, No 5 (2018)
Original paper
Submitted: 2018-02-01
Accepted: 2018-04-22
Published online: 2018-08-03
View PDF Download PDF file
Get Citation

The relation of pituitary adenomas invasiveness and the proliferative index measured by immunoexpression of topoisomerase IIα

Borys M. Kwinta1, Aleksander Wilk1, Małgorzata Trofimiuk-Muldner2, Ewelina Grzywna1, Roger M. Krzyżewski1, Krzysztof Stachura1, Dariusz Adamek3
DOI: 10.5603/EP.a2018.0050
·
Pubmed: 30074233
·
Endokrynol Pol 2018;69(5):530-535.
Affiliations
  1. Department of Neurosurgery and Neurotraumatology, Jagiellonian University Medical College, Kraków, Poland, Botaniczna 3, 31-501 Kraków, Poland
  2. Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland
  3. Department of Neuropathology, Jagiellonian University Medical College, Kraków, Poland, Botaniczna 3, 31-501 Kraków, Poland

open access

Vol 69, No 5 (2018)
Original Paper
Submitted: 2018-02-01
Accepted: 2018-04-22
Published online: 2018-08-03

Abstract

Introduction: Cavernous sinus invasion by pituitary adenoma affects surgical procedure radicality and consequently the postoperative course and prognosis in pituitary adenoma treatment. The search for pituitary adenoma aggressive behaviour markers is still a matter of debate.

Material and methods: This study evaluates the relation of pituitary adenoma invasiveness to the expression of topoisomerase IIα in 72 patients who underwent transsphenoidal pituitary surgery. The assessment of tumour growth was conducted according to the Hardy scale as modified by Wilson and the Knosp scale. Topoisomerase IIα expression in tumour specimens was evaluated using immunohistochemical staining.

Results: There was a correlation between the Knosp scale degree and the topoisomerase IIα expression (Spearman R = 0.3611, p < 0.005). The Kruskal-Wallis H test (p = 0.0034) showed that there was a statistically significant topoisomerase IIα expression increase in tumours classified as grade E on the Hardy scale. The topoisomerase IIα expression correlated also with tumour size (Spearman R = 0.4117, p < 0.001). Higher levels of expression were observed in macroadenomas, as compared to microadenomas (p < 0.05, Mann-Whitney test). Topoisomerase IIα expression correlated with cavernous sinus invasion.

Conclusions: The topoisomerase IIα expression correlated more with invasiveness than with extensiveness, which might make it an eminently useful marker in the assessment of aggressive pituitary adenoma behaviour.

Abstract

Introduction: Cavernous sinus invasion by pituitary adenoma affects surgical procedure radicality and consequently the postoperative course and prognosis in pituitary adenoma treatment. The search for pituitary adenoma aggressive behaviour markers is still a matter of debate.

Material and methods: This study evaluates the relation of pituitary adenoma invasiveness to the expression of topoisomerase IIα in 72 patients who underwent transsphenoidal pituitary surgery. The assessment of tumour growth was conducted according to the Hardy scale as modified by Wilson and the Knosp scale. Topoisomerase IIα expression in tumour specimens was evaluated using immunohistochemical staining.

Results: There was a correlation between the Knosp scale degree and the topoisomerase IIα expression (Spearman R = 0.3611, p < 0.005). The Kruskal-Wallis H test (p = 0.0034) showed that there was a statistically significant topoisomerase IIα expression increase in tumours classified as grade E on the Hardy scale. The topoisomerase IIα expression correlated also with tumour size (Spearman R = 0.4117, p < 0.001). Higher levels of expression were observed in macroadenomas, as compared to microadenomas (p < 0.05, Mann-Whitney test). Topoisomerase IIα expression correlated with cavernous sinus invasion.

Conclusions: The topoisomerase IIα expression correlated more with invasiveness than with extensiveness, which might make it an eminently useful marker in the assessment of aggressive pituitary adenoma behaviour.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

pituitary adenoma, Knosp scale, topoisomerase IIα expression, cavernous sinuses invasion

About this article
Title

The relation of pituitary adenomas invasiveness and the proliferative index measured by immunoexpression of topoisomerase IIα

Journal

Endokrynologia Polska

Issue

Vol 69, No 5 (2018)

Article type

Original paper

Pages

530-535

Published online

2018-08-03

Page views

2288

Article views/downloads

1380

DOI

10.5603/EP.a2018.0050

Pubmed

30074233

Bibliographic record

Endokrynol Pol 2018;69(5):530-535.

Keywords

pituitary adenoma
Knosp scale
topoisomerase IIα expression
cavernous sinuses invasion

Authors

Borys M. Kwinta
Aleksander Wilk
Małgorzata Trofimiuk-Muldner
Ewelina Grzywna
Roger M. Krzyżewski
Krzysztof Stachura
Dariusz Adamek

References (39)
  1. Faglia G. Epidemiology and pathogenesis of pituitary adenomas. Acta Endocrinol. 1993; 129(Suppl 1): 1–5.
    PubMed
  2. Kontogeorgos G. Classification and pathology of pituitary tumors. Endocrine. 2005; 28(1): 27–35.
    CrossRefPubMed
  3. Korali Z, Müller A, Schopol J. Hypophysentumoren und Kraniopharyngeome. Manual — Hirntumoren und primäre Tumoren des Rückenmarks. Tumorzentrum, München 2001: 89–108.
  4. Elster AD. Imaging of the sella: anatomy and pathology. Semin Ultrasound CT MR. 1993; 14(3): 182–194.
    PubMed
  5. Greenberg M. Handbook of neurosurgery. Thieme, New York 2001.
  6. Rennert J, Doerfler A. Imaging of sellar and parasellar lesions. Clin Neurol Neurosurg. 2007; 109(2): 111–124.
    CrossRefPubMed
  7. Wilson C. Neurosurgical management of large and invasive pituitary tumours. In: Tindal G, Collins W. ed. Clinical management of pituitary disorders. Raven Press, New York 1979: 335–342.
  8. Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993; 33(4): 610–617; discussion 617.
    PubMed
  9. Ahmadi J, North CM, Segall HD, et al. Cavernous sinus invasion by pituitary adenomas. AJR Am J Roentgenol. 1986; 146(2): 257–262.
    CrossRefPubMed
  10. Fahlbusch R, Buchfelder M. Transsphenoidal surgery of parasellar pituitary adenomas. Acta Neurochir (Wien). 1988; 92(1-4): 93–99.
    PubMed
  11. Chacko G, Chacko AG, Lombardero M, et al. Clinicopathologic correlates of giant pituitary adenomas. J Clin Neurosci. 2009; 16(5): 660–665.
    CrossRefPubMed
  12. Sol YuLi, Lee SK, Choi HS, et al. Evaluation of MRI criteria for cavernous sinus invasion in pituitary macroadenoma. J Neuroimaging. 2014; 24(5): 498–503.
    CrossRefPubMed
  13. Horvath E, Lloyd RV, Kovacs K. Plurihormonal adenoma. In: Delellis RA, Lloyd RV, Heitz PU, Eng C. ed. World Health Organisation Classification of Tumours: Pathology & Genetics — Tumours of Endocrine Organs. IARC Press, Lyon 2004: 35.
  14. Kontogeorgos G, Watson Jr, Lindell EP. Growth hormone producing adenoma. In: Delellis RA, Lloyd RV, Heitz PU, Eng C. ed. World Health Organisation Classification of Tumours: Pathology & Genetics — Tumours of Endocrine Organs. IARC Press, Lyon 2004: 14–19.
  15. Lloyd RV, Kovacs K, Young Jr WF. Pituitary tumours: introduction. In: Delellis RA, Lloyd RV, Heitz PU, Eng C. ed. World Health Organisation Classification of Tumours: Pathology & Genetics — Tumours of Endocrine Organs. IARC Press, Lyon 2004: 10–13.
  16. Kaltsas GA, Nomikos P, Kontogeorgos G, et al. Clinical review: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005; 90(5): 3089–3099.
    CrossRefPubMed
  17. Heaney A. Management of aggressive pituitary adenomas and pituitary carcinomas. J Neurooncol. 2014; 117(3): 459–468.
    CrossRefPubMed
  18. Paek KI, Kim SH, Song SH, et al. Clinical significance of Ki-67 labeling index in pituitary macroadenoma. J Korean Med Sci. 2005; 20(3): 489–494.
    CrossRefPubMed
  19. Fahlbusch R, Buslei R. The WHO classification of pituitary tumours: a combined neurosurgical and neuropathological view. Acta Neuropathol. 2006; 111(1): 86–87.
    CrossRefPubMed
  20. Grossman AB. The 2004 World Health Organization classification of pituitary tumors: is it clinically helpful? Acta Neuropathol. 2006; 111(1): 76–77.
    CrossRefPubMed
  21. Saeger W, Lüdecke DK, Buchfelder M, et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 2007; 156(2): 203–216.
    CrossRefPubMed
  22. Turner HE, Wass JA. Are markers of proliferation valuable in the histological assessment of pituitary tumours? Pituitary. 1999; 1(3-4): 147–151.
    PubMed
  23. Kontogeorgos G. Predictive markers of pituitary adenoma behavior. Neuroendocrinology. 2006; 83(3-4): 179–188.
    CrossRefPubMed
  24. Bildrici K, Tel N, Ozalp SS, et al. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma. Eur J Gynaecol Oncol. 2002; 23(6): 540–544.
    PubMed
  25. Boege F, Gieseler F, Biersack H, et al. The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignancies. Eur J Clin Chem Clin Biochem. 1992; 30(2): 63–68.
    PubMed
  26. Koshiyama M, Fujii H, Kinezaki M, et al. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Anticancer Res. 2001; 21(4B): 2925–2932.
    PubMed
  27. Depowski PL, Rosenthal SI, Brien TP, et al. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Mod Pathol. 2000; 13(5): 542–547.
    CrossRefPubMed
  28. Feng Y, Zhang H, Gao W, et al. Expression of DNA topoisomerase II-α: Clinical significance in laryngeal carcinoma. Oncol Lett. 2014; 8(4): 1575–1580.
    CrossRefPubMed
  29. Kiyoshi M. Immunocytochemical study of 150 tumours with clinicopathologic correlation. Cancer. 1983; 52: 648–653.
    PubMed
  30. Vidal S, Kovacs K, Horvath E, et al. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol. 2002; 15(11): 1205–1212.
    CrossRefPubMed
  31. Di Chiro G, Nelson KB. The volume of the sella turcica. Am J Roentgenol Radium Ther Nucl Med. 1962; 87: 989–1008.
    PubMed
  32. Goel A, Nadkarni T, Muzumdar D, et al. Giant pituitary tumors: a study based on surgical treatment of 118 cases. Surg Neurol. 2004; 61(5): 436–45; discussion 445.
    CrossRefPubMed
  33. Cottier JP, Destrieux C, Brunereau L, et al. Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology. 2000; 215(2): 463–469.
    CrossRefPubMed
  34. Sarkar S, Chacko AG, Chacko G. Clinicopathological correlates of extrasellar growth patterns in pituitary adenomas. J Clin Neurosci. 2015; 22(7): 1173–1177.
    CrossRefPubMed
  35. Landolt AM, Shibata T, Kleihues P. Growth rate of human pituitary adenomas. J Neurosurg. 1987; 67(6): 803–806.
    CrossRefPubMed
  36. Yilmaz M, Vural E, Koc K, et al. Cavernous sinus invasion and effect of immunohistochemical features on remission in growth hormone secreting pituitary adenomas. Turk Neurosurg. 2015; 25(3): 380–388.
    CrossRefPubMed
  37. Moldovan IM, Melincovici C, Mihu C, et al. Diagnostic criteria in invasive pituitary adenomas. Rom Neurosurg. 2016; 30(3): 345–359.
    CrossRef
  38. Wolfsberger S, Wunderer J, Zachenhofer I, et al. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir (Wien). 2004; 146(8): 831–839.
    CrossRefPubMed
  39. Trofimiuk-Müldner M, Bałdys-Waligórska A, Sokołowski G, et al. Topoisomerase IIα as a prognostic factor in pituitary tumors. Pol Arch Med Wewn. 2014; 124(10): 500–508.
    PubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl